The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy

Paola Zordan, Clara Sciorati, Lara Campana, Lucia Cottone, Emilio Clementi, Patrizia Rovere Querini, Silvia Brunelli

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Inflammation plays a crucial role in muscle remodeling and repair after acute and chronic damage, in particular in muscular dystrophies, a heterogeneous group of genetic diseases leading to muscular degeneration. Defect of nitric oxide (NO) generation is a key pathogenic event in muscular dystrophies, thus NO donors have been explored as new therapeutics for this disease. We have investigated the immune-modulating effect of one of such drugs, molsidomine, able to slow the progression of muscular dystrophy in the α-Sarcoglican- null mice, a model for the limb girdle muscular dystrophy 2D, sharing several hallmarks of muscle degeneration with other muscular dystrophies. α-Sarcoglican-null mice were treated with molsidomine and drug effects on the inflammatory infiltrates and on muscle repair were assessed at selected time points. We found that molsidomine treatment modulates effectively the characteristics of the inflammatory infiltrate within dystrophic muscles, enhancing its healing function. Initially molsidomine amplified macrophage recruitment, promoting a more efficient clearance of cell debris and effective tissue regeneration. At a later stage molsidomine decreased significantly the extent of the inflammatory infiltrate, whose persistence exacerbates muscle damage: most of the remaining macrophages displayed characteristics of the transitional population, associated with reduced fibrosis and increased preservation of the muscle tissue. The dual action of molsidomine, the already known NO donation and the immunomodulatory function we now identified, suggests that it has a unique potential in tissue healing during chronic muscle damage. This, alongside its already approved use in human, makes molsidomine a drug with a significant therapeutic potential in muscular dystrophies.

Original languageEnglish
Pages (from-to)296-303
Number of pages8
JournalEuropean Journal of Pharmacology
Volume715
Issue number1-3
DOIs
Publication statusPublished - 2013

Fingerprint

Molsidomine
Nitric Oxide Donors
Muscular Dystrophies
Muscles
Nitric Oxide
Macrophages
Limb-Girdle Muscular Dystrophies
Pharmaceutical Preparations
Inborn Genetic Diseases
Population Characteristics
Regeneration
Fibrosis
Inflammation
Therapeutics

Keywords

  • α-Sarcoglican
  • Macrophages
  • Molsidomine
  • Muscular dystrophy
  • Nitric oxide

ASJC Scopus subject areas

  • Pharmacology

Cite this

The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy. / Zordan, Paola; Sciorati, Clara; Campana, Lara; Cottone, Lucia; Clementi, Emilio; Querini, Patrizia Rovere; Brunelli, Silvia.

In: European Journal of Pharmacology, Vol. 715, No. 1-3, 2013, p. 296-303.

Research output: Contribution to journalArticle

Zordan, Paola ; Sciorati, Clara ; Campana, Lara ; Cottone, Lucia ; Clementi, Emilio ; Querini, Patrizia Rovere ; Brunelli, Silvia. / The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy. In: European Journal of Pharmacology. 2013 ; Vol. 715, No. 1-3. pp. 296-303.
@article{7ed78dac28244a92a2ea011e0a4dc43d,
title = "The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy",
abstract = "Inflammation plays a crucial role in muscle remodeling and repair after acute and chronic damage, in particular in muscular dystrophies, a heterogeneous group of genetic diseases leading to muscular degeneration. Defect of nitric oxide (NO) generation is a key pathogenic event in muscular dystrophies, thus NO donors have been explored as new therapeutics for this disease. We have investigated the immune-modulating effect of one of such drugs, molsidomine, able to slow the progression of muscular dystrophy in the α-Sarcoglican- null mice, a model for the limb girdle muscular dystrophy 2D, sharing several hallmarks of muscle degeneration with other muscular dystrophies. α-Sarcoglican-null mice were treated with molsidomine and drug effects on the inflammatory infiltrates and on muscle repair were assessed at selected time points. We found that molsidomine treatment modulates effectively the characteristics of the inflammatory infiltrate within dystrophic muscles, enhancing its healing function. Initially molsidomine amplified macrophage recruitment, promoting a more efficient clearance of cell debris and effective tissue regeneration. At a later stage molsidomine decreased significantly the extent of the inflammatory infiltrate, whose persistence exacerbates muscle damage: most of the remaining macrophages displayed characteristics of the transitional population, associated with reduced fibrosis and increased preservation of the muscle tissue. The dual action of molsidomine, the already known NO donation and the immunomodulatory function we now identified, suggests that it has a unique potential in tissue healing during chronic muscle damage. This, alongside its already approved use in human, makes molsidomine a drug with a significant therapeutic potential in muscular dystrophies.",
keywords = "α-Sarcoglican, Macrophages, Molsidomine, Muscular dystrophy, Nitric oxide",
author = "Paola Zordan and Clara Sciorati and Lara Campana and Lucia Cottone and Emilio Clementi and Querini, {Patrizia Rovere} and Silvia Brunelli",
year = "2013",
doi = "10.1016/j.ejphar.2013.05.007",
language = "English",
volume = "715",
pages = "296--303",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",
number = "1-3",

}

TY - JOUR

T1 - The nitric oxide-donor molsidomine modulates the innate inflammatory response in a mouse model of muscular dystrophy

AU - Zordan, Paola

AU - Sciorati, Clara

AU - Campana, Lara

AU - Cottone, Lucia

AU - Clementi, Emilio

AU - Querini, Patrizia Rovere

AU - Brunelli, Silvia

PY - 2013

Y1 - 2013

N2 - Inflammation plays a crucial role in muscle remodeling and repair after acute and chronic damage, in particular in muscular dystrophies, a heterogeneous group of genetic diseases leading to muscular degeneration. Defect of nitric oxide (NO) generation is a key pathogenic event in muscular dystrophies, thus NO donors have been explored as new therapeutics for this disease. We have investigated the immune-modulating effect of one of such drugs, molsidomine, able to slow the progression of muscular dystrophy in the α-Sarcoglican- null mice, a model for the limb girdle muscular dystrophy 2D, sharing several hallmarks of muscle degeneration with other muscular dystrophies. α-Sarcoglican-null mice were treated with molsidomine and drug effects on the inflammatory infiltrates and on muscle repair were assessed at selected time points. We found that molsidomine treatment modulates effectively the characteristics of the inflammatory infiltrate within dystrophic muscles, enhancing its healing function. Initially molsidomine amplified macrophage recruitment, promoting a more efficient clearance of cell debris and effective tissue regeneration. At a later stage molsidomine decreased significantly the extent of the inflammatory infiltrate, whose persistence exacerbates muscle damage: most of the remaining macrophages displayed characteristics of the transitional population, associated with reduced fibrosis and increased preservation of the muscle tissue. The dual action of molsidomine, the already known NO donation and the immunomodulatory function we now identified, suggests that it has a unique potential in tissue healing during chronic muscle damage. This, alongside its already approved use in human, makes molsidomine a drug with a significant therapeutic potential in muscular dystrophies.

AB - Inflammation plays a crucial role in muscle remodeling and repair after acute and chronic damage, in particular in muscular dystrophies, a heterogeneous group of genetic diseases leading to muscular degeneration. Defect of nitric oxide (NO) generation is a key pathogenic event in muscular dystrophies, thus NO donors have been explored as new therapeutics for this disease. We have investigated the immune-modulating effect of one of such drugs, molsidomine, able to slow the progression of muscular dystrophy in the α-Sarcoglican- null mice, a model for the limb girdle muscular dystrophy 2D, sharing several hallmarks of muscle degeneration with other muscular dystrophies. α-Sarcoglican-null mice were treated with molsidomine and drug effects on the inflammatory infiltrates and on muscle repair were assessed at selected time points. We found that molsidomine treatment modulates effectively the characteristics of the inflammatory infiltrate within dystrophic muscles, enhancing its healing function. Initially molsidomine amplified macrophage recruitment, promoting a more efficient clearance of cell debris and effective tissue regeneration. At a later stage molsidomine decreased significantly the extent of the inflammatory infiltrate, whose persistence exacerbates muscle damage: most of the remaining macrophages displayed characteristics of the transitional population, associated with reduced fibrosis and increased preservation of the muscle tissue. The dual action of molsidomine, the already known NO donation and the immunomodulatory function we now identified, suggests that it has a unique potential in tissue healing during chronic muscle damage. This, alongside its already approved use in human, makes molsidomine a drug with a significant therapeutic potential in muscular dystrophies.

KW - α-Sarcoglican

KW - Macrophages

KW - Molsidomine

KW - Muscular dystrophy

KW - Nitric oxide

UR - http://www.scopus.com/inward/record.url?scp=84885483185&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84885483185&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2013.05.007

DO - 10.1016/j.ejphar.2013.05.007

M3 - Article

VL - 715

SP - 296

EP - 303

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

IS - 1-3

ER -